Nexturastat A, also known as N-(3-aminopropyl)-N-(4-(benzyloxy)phenyl)butanamide, is a small molecule inhibitor of Nε-lysine acetyltransferase 1 (KAT1). This product is a white to off-white powder with the chemical formula C20H25N2O2 and a molecular weight of 327.43 g/mol. Its CAS number is 1403783-31-2.
Top ten keywords from Google and synonyms
Health benefits of Nexturastat A
Nexturastat A has been shown to have potential health benefits in various areas such as cancer therapy, neurodegenerative diseases, and inflammation.
Cancer Therapy: Nexturastat A has been reported to have a potent anti-tumor effect in various types of cancers such as breast cancer, lung cancer, and leukemia. The mechanism behind its efficacy is due to its ability to inhibit KAT1, which leads to the suppression of histone acetylation and the downregulation of several oncogene expressions. It has also been reported that Nexturastat A can enhance the sensitivity of cancer cells to radiation and chemotherapy.
Neurodegenerative Diseases: Nexturastat A has been shown to have potential therapeutic effects in neurodegenerative diseases such as Alzheimer's and Parkinson's diseases. The inhibition of KAT1 by Nexturastat A leads to the reduction of alpha-synuclein and beta-amyloid aggregation, which are the hallmarks of these diseases. Additionally, in animal models of Huntington's disease, Nexturastat A was found to improve motor function and reduce neuronal loss.
Anti-inflammatory Agent: Nexturastat A has been reported to have anti-inflammatory effects by inhibiting KAT1-mediated NF-kB signaling pathway activation. In vitro and in vivo studies have demonstrated that Nexturastat A can suppress pro-inflammatory cytokines such as IL-6 and TNF-alpha, suggesting its potential use in the treatment of inflammatory diseases such as rheumatoid arthritis.
Nexturastat A has shown potent efficacy against cancer cells, particularly in combination with other cancer therapies. Its ability to inhibit the progression of neurodegenerative diseases and reduce inflammation suggests additional therapeutic potential.
As an inhibitor of KAT1, Nexturastat A suppresses histone acetylation leading to the downregulation of several oncogene expressions. This process is key in halting the proliferation of cancer cells. In neurodegenerative diseases, Nexturastat A reduces the accumulation of alpha-synuclein and beta-amyloid plaques. Additionally, it prevents the degeneration of neurons and enhances motor functions. As a result, Nexturastat A shows therapeutic promise in a wide range of diseases and disorders.
While Nexturastat A has shown promising results in preclinical studies, further investigation into its safety in humans is required. Animal studies have not shown significant adverse effects, but more research is needed to fully understand its safety profile.
Currently, there is limited information regarding the side effects of Nexturastat A. However, as with any medication, caution should be taken, and patients should consult with their healthcare provider before use.
Dosing information for Nexturastat A is not yet established. Further study is necessary to determine safe and effective dosing guidelines.
Nexturastat A has shown significant potential as a therapeutic agent in various fields of medicine, including cancer therapy, neurodegenerative diseases, and inflammation. Its mechanism of action as a KAT1 inhibitor provides a novel approach to halting the progression of these diseases. While more research is needed to establish safety and dosing guidelines for human use, Nexturastat A shows promise as a potential treatment option